Section Arrow
Quote
GLMD.NASDAQ
- Galmed Pharmaceuticals Ltd
Quotes are at least 15-min delayed:2025/07/21 06:37 EDT
Pre Market
Last
 1.91
+0.08 (+4.37%)
Bid
1.9
Ask
2.2
High 2.01 
Low 1.9 
Volume 3911 
Regular Hours
Last
 1.83
-0.5 (-21.46%)
Day High 
2.3 
Prev. Close
2.33 
1-M High
2.34 
Volume 
1.15M 
Bid
1.9
Ask
2.2
Day Low
1.77 
Open
2.3 
1-M Low
1.6301 
Market Cap 
5.26M 
Currency USD 
P/E 0.02 
%Yield -- 
10-SMA 2.06 
20-SMA 1.93 
50-SMA 1.63 
52-W High 23.8 
52-W Low 1.15 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-6.60/-1.01
Enterprise Value
5.26M
Balance Sheet
Book Value Per Share
7.47
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
TELOTelomir Pharmaceuticals2.28+1.07+88.43%-- 
Pre Market 2.02 -0.26 -11.40%
SRPTSarepta Therapeutics14.075-7.895-35.94%15.76PE
Pre Market 13.325 -0.75 -5.33%
NCNANuCana plc0.0477+0.0009+1.92%-- 
Pre Market 0.0479 +0.0002 +0.42%
RXRXRecursion Pharmaceuticals5.84+0.32+5.80%-- 
Pre Market 6.19 +0.35 +5.99%
MEIPMEI Pharma5.92+1.42+31.56%1.09PE
Pre Market 6.08 +0.16 +2.70%
Quotes are at least 15-min delayed：2025/07/21 06:37 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development of Aramchol. exclusively on developing Aramchol for the treatment of liver disease and were previously developing Aramchol for primary sclerosing cholangitis, PSC, and exploring the feasibility of developing Aramchol for other fibro-inflammatory indications outside of NASH and fibrosis. The company is currently seeking to advance the development of Aramchol for oncological indications outside of NASH and fibrosis.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.